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Abstract
Until quite recently, the management of children with growth hormone deficiency 
(GHD) had focussed on the use of recombinant human GH (rhGH) therapy to normalise 
final adult height. However, research over the past two decades that has demonstrated 
deficits in bone health and cardiac function, as well as impaired quality of life in adults 
with childhood-onset GHD (CO-GHD), has questioned this practice. Some of these studies 
suggested that there may be short-term benefits of rhGH in certain group of adolescents 
with GHD during transition, although the impact of GHD and replacement during 
the transition period has not been adequately investigated and its long-term benefits 
remain unclear. GH therapy remains expensive and well-designed long-term studies are 
needed to determine the cost effectiveness and clinical benefit of ongoing rhGH during 
transition and further into adulthood. In the absence of compelling data to justify 
widespread continuation of rhGH into adult life, there are several questions related 
to its use that remain unanswered. This paper reviews the effects of growth hormone 
deficiency on bone health, cardiovascular function, metabolic profile and quality of life 
during transition and young adulthood.
Introduction
Growth hormone deficiency (GHD) is an endocrine 
condition that can potentially impact on an individual’s 
life from childhood, adolescence to young adulthood and 
beyond. In UK, the prevalence of congenital childhood-
onset GHD (CO-GHD) has been estimated to be about 
1 in 3500–4000 live births, whereas the prevalence of 
adult onset (AO-GHD) in addition to those with previous 
CO-GHD is also about 1 in 3000 of the UK adult population 
(1, 2). In addition to linear growth, the GH–IGF axis has 
important metabolic effects on a variety of target tissues 
(Fig. 1). Historically, treatment with recombinant human 
GH (rhGH) was discontinued at final height as defined 
by a growth velocity less than 2 cm/year (1). However, 
extensive research over the past two decades that has 
demonstrated deficits in bone health and cardiac function, 
together with impaired quality of life in adults with 
CO-GHD after completion of childhood treatment (3, 4, 
5, 6), has questioned this practice. Although there are a 
number of reports of a beneficial impact on continuation 
of rhGH therapy beyond attainment of final height, there 
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are several studies where the results are less conclusive in 
determining the clinical and cost effectiveness of rhGH 
treatment during transition, especially with treatment 
costing up to £5000 per year in adulthood (7). The current 
guideline has approved continuation of GH replacement 
in those who were confirmed to have persistent GHD 
through the transition phase, although the evidence base 
underlying this recommendation is limited (8).
The primary aim of this review was to identify what 
evidence is available on the risks of GHD and the benefits 
of rhGH therapy during the transition period in the fol-
lowing areas: bone mass, body compositions, metabolic 
profiles and quality of life.
The literature search was conducted in the following 
databases: MEDLINE(Ovid), PubMed, Cochrane Library 
databases, Web of Science and Scopus in December 2015. 
The inclusion criteria for studies were randomised con-
trolled clinical trials, longitudinal and case–control studies 
comparing discontinuation/continuation/and recom-
mencing rhGH therapy in young adult with CO-GHD 
(aged between 15 and 30 years). Exclusion criteria were 
animal studies, studies of adults with CO-GHD, adult-
onset GHD, short stature and other endocrine conditions. 
Key outcome measures of selected studies are reported in 
tables and in the text. Figure 2 presents a brief summary 
of the literature review process and selection of studies.
Consequences of rhGH cessation and 
replacement during transition
Bone mass and risk of fracture
Bone mass: Cross-sectional and observational studies of 
bone density in rhGH-treated children with CO-GHD at 
time of completing linear growth have shown inconsistent 
findings with either low areal bone mineral density (BMD) 
(g/cm2), normal or slightly reduced total body (TB) BMD, 
bone mineral density (BMC) and lumber spinal (LS) 
volumetric mineral apparent density (BMAD) (g/cm3) 
(9, 10, 11, 12, 13) (Table  1). Early rhGH treatment in 
Figure 1
GH–IGF1 axis and actions in bone, muscle and body metabolism. GH secretion is regulated by three peptides: GH-releasing hormone (GHRH), ghrelin-
stimulating GH release and somatostatin (SS)-inhibiting GH release. In circulation, GH stimulates the liver and other peripheral tissues to produce 
insulin-like growth factor-1(IGF1). GH/IGF1 stimulates longitudinal growth, enhances bone mass, and regulates bone metabolism. GH promotes the 
positive protein balance in skeletal muscle and has lipolytic effects which may play a role in maintaining glucose homeostasis with decreased insulin 
sensitivity which all promote cardiovascular system (CVS) functional capacity and maximal oxygen consumption (VO2 max).
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childhood results in better indices of bone mass on 
completion of treatment at final height (9). Beyond 
transition, a longitudinal study reported a delayed timing 
of peak bone mass at LS, and a rapid decline over the 
following 2 years was observed in adolescents with 
CO-GHD who discontinued rhGH after final height 
compared with controls (14).
Therefore, there was a concern that childhood rhGH-
treated subjects with CO-GHD may not achieve peak bone 
mass as a consequence of discontinuing GH treatment at 
final height.
Over the past few decades, a series of clinical trials 
studies have been conducted to examine the effects of 
continuation, discontinuation, and recommencement 
of rhGH during the transition phase of adolescents with 
CO-GHD, but thus far, they yield conflicting results 
(Table  2). Continuation of rhGH is reported to be 
associated with an increase in TB-BMC and LS-BMD in the 
range 3–6% after either 1 year (4) or 2 years (15, 16, 17) 
as assessed with dual-energy X-ray absorptiometry (DXA). 
However, this net gain is similar to what would be expected 
in the normal population during this stage (18, 19). It was 
also reported that bone mass does continue to increase in 
adolescents who discontinue rhGH therapy, yet the net 
gain is about half of that achieved by adolescents who 
continue rhGH therapy (15, 16).
By contrast, other studies have shown no change in 
BMD up to 2 years following discontinuation of rhGH 
after attainment of final height (11) and no benefit from 
continuation of rhGH 2 years after final height (20, 
21). It was, therefore, proposed that 2 years was a safe 
period to be without rhGH, after which rhGH treatment 
would be recommenced in confirmed GHD patients. 
However, according to Tritos and coworkers, an interval of 
Figure 2
Flow diagram of the literature review process and selection of studies.
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6–12 months off GH therapy was associated with a lower 
femoral neck (FN)-BMD, and therefore, a firm recommen-
dation of a safe duration off rhGH replacement therapy 
with regard to BMD cannot be made (22).
Dose dependency with regard to the impacts of rhGH 
on bone mass has only been studied in two studies; a 
2-year randomised controlled trial found a higher dose 
(25 µg/kg/day) of rhGH impact differently in favour of 
bone mass than a lower dose (12.5 µg/kg/day) (16), when 
no significant difference was found in another similar 
study over same period (15).
It is noteworthy that among all the studies reported in 
Table 2, there was a considerable variability in definition 
of GHD during transition and retesting in terms of 
stimulated GH peak cut-offs, population heterogeneity 
between isolated GHD/multiple pituitary hormone 
deficiencies (MPHD) and aetiologies of GHD, and duration 
of discontinuation of rhGH after final height, rhGH dose 
during childhood and after final height. In addition, 
measurement of bone density using DXA in children and 
adolescents with CO-GHD is challenging by confounding 
effects of body size and composition, with no consensus 
as to what is the optimal adjustment to express bone 
densitometry, additional to the lack of reference data 
that adjusts for different confounding factors of growth-
impaired children and adolescents (23). Therefore, this 
variation may substantially affect the interpretation of the 
results, limiting the analysis to certain groups of patients 
with the greatest benefit from the rhGH treatment during 
transition.
It is also increasingly recognised that the bone health 
and fracture prediction is dependent not only on bone 
density but also on bone geometry and microarchitecture 
(24). The consequences of GHD and rhGH replacement 
on bone geometry and structure in subjects with CO-GHD 
have been investigated in few studies demonstrating 
reduced cortical area and thickness but normal cortical 
and trabecular density at time of diagnosis during 
childhood which was significantly reduced after 
1 year of rhGH treatment (25). At final height and after 
discontinuation of rhGH, marked lower height corrected 
cortical thickness and wider endosteal circumference but 
a normal cortical and trabecular density compared with 
a healthy reference population (26). Two years of rhGH 
replacement results in a significant increase in cortical 
thickness compared with non-treated control group 
of young adults with CO-GHD (27), when a significant 
reduction in cortical bone area and thickness in untreated 
CO-GHD adults compared with AO-GHD was reported 
elsewhere (28). One recent study with more advanced T
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imaging (high-resolution magnetic resonance imaging 
(micro-MRI)) investigated the bone structure of ten young 
adults with hypogonadism and/or CO-GHD and reported 
that the ratio of apparent bone volume to total volume 
(appBV/TV) and apparent trabecular number (appTbN) 
was significantly lower in GHD than in the age-matched 
control group (29), although the relationship between 
trabecular size and number to bone fragility and fracture 
risk has not been established yet.
Risk of fracture: Although data on the association 
between bone density and fractures in children are limited, 
it is generally established that the fracture risk may be higher 
in healthy children and adolescents who have low BMC 
and bone accrual (30, 31). The association between GHD, 
low bone mass and subsequent fracture risk in adolescents 
and young adults with CO-GHD is less clear than that 
observed in adults with GHD and hypopituitarism (32, 33). 
However, in these studies, it was not known if that is a result 
of being GH deficient per se or due to other pituitary hormone 
deficiencies. Accordingly, other studies showed no evidence 
that isolated GHD (IGHD) may increase fracture risk (34, 35). 
With regard to the impact of rhGH replacement therapy on 
fracture rates, childhood studies suggest a protective effect 
of rhGH treatment in children with GHD with a four-fold 
decrease in fracture frequency from diagnosis to final height 
compared with matched healthy controls, but fracture 
prevalence increased to 3% at final height particularly in 
those with reduced lumbar BMD (Z-score <1) (12). Studies 
in adults involving both CO- and AO-GHD reported a 
lower incidence of fracture risk in CO-GHD compared with 
AO-(32, 34, 36), with a double incidence of non-osteoporotic 
fracture in women with CO-GHD compared with men with 
CO-GHD despite continuation of rhGH treatment (36) 
(Table 3). In view of these studies, CO-GHD was queried 
as a cause of osteoporosis due to the lack of evidence for 
increased fracture risk in children and adults with CO-GHD 
or severe GH resistance (37).
To summarise this section, data thus far demonstrate 
contradictory results with most studies, but not all, show-
ing a small increase in bone density and mineralisation 
during rhGH therapy in transition. However, the extent 
of GHD and replacement with regard to bone density and 
architecture is unclear. Using more advanced non-invasive 
imaging tools, which assess bone quality, may provide a 
greater insight into the effects of GHD and rhGH on bone.
In addition, there is an insufficient evidence of 
increased fracture risk in patients with CO-GHD as the 
reporting of the risk of fracture in GHD had considerable Ta
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limitations. Therefore, it remains unclear whether early 
adulthood rhGH treatment would offer protection from 
osteoporosis and fracture risk in late adulthood. Prospec-
tive long-term follow-up studies are still lacking.
Body composition and muscle strength
During transition, studies indicate that patients who were 
reconfirmed to have persistent GHD and discontinued 
rhGH in the transition period showed decreased lean 
mass (LM) (−8%) and increased fat mass (FM) (10–17%) 
compared with either sufficient or those who continued 
rhGH after 2 years of observation (21, 38, 39, 40). A 
study measured the early changes in body composition 
in CO-GHD patients after a median of 6 months after 
cessation of rhGH in patients who attained final height. 
The authors stated that patients with persistent GHD 
(n = 37) had a significantly lower muscle cross-sectional 
area (CSA) Z-score (−0.24 ± 1.6 vs 0.44 ± 1.42, P < 0.03), a 
two-fold increase in fat CSA (1329 + 100 mm2 vs 878 + 91 
mm2) compared with patients who were no longer GH 
deficient at final height (26). Recommencement of 
rhGH therapy was documented to result in a marked 
improvement in body composition, with an increase in 
LM by 14%, and a reduction in FM by −7% over 2 years of 
replacement (16, 41), yet long-term studies are scarce in 
determining the sustainability of these changes. A study 
by Mauras and coworkers is the only one that showed 
no significant difference in the changes of LM and FM 
from baseline to 2 year between continuation of rhGH as 
compared with placebo-treated or control subjects (20).
In terms of the relationship between CO-GHD, 
rhGH and muscle strength, it has been reported that 
discontinuation of rhGH in CO-GHD for 2 years has 
potentially negative consequences on muscular strength 
in some studies (3, 42), but not all (20, 39). From a recently 
published cross-sectional study investigating muscle 
strength and body composition of 18 males with CO-GHD 
(aged 18–30 years), of those, 9 (4-IGHD) were reconfirmed 
to have GHD after re-evaluating them at final height during 
transition. This study suggested that muscle strength as 
measured by an isokinetic dynamometer was lower in those 
with persistent GHD compared with sufficient and healthy 
controls (P < 0.05) (13). However, data so far do not support 
the use of rhGH therapy to increase muscle strength during 
transition and young adulthood (16, 21, 39).
The majority of research has shown favourable dif-
ferences in body composition with recommencing rhGH 
during transition, although encouraging further research 
in the field with long-term follow-up is needed.
Cardiovascular risks and glucose metabolism
Epidemiological evidence shows negative effects of GHD 
on cardiovascular risk factors including unfavourable 
lipid profiles, hypercoagulability, atherosclerosis and 
endothelial dysfunction, which could contribute to 
increased morbidity and mortality of adults with GHD 
and hypopituitarism without rhGH therapy (43), 
with a higher hazard ratio in AO-GHD compared with 
CO-GHD (3.0 (2.1–4.4) vs 1.4 (1.0–1.8), respectively (44). 
Cardiovascular risk in CO-GHD and benefits of rhGH 
have been documented during childhood (45, 46) and 
adolescence (47).
Lipid profiles: It has been well established that 
discontinuation of rhGH therapy after final height results 
in an increase in unfavourable lipid profile (26, 41, 48, 
49), while the effect of restarting rhGH therapy remains 
unclear. Some studies have shown reversal in the levels of 
unfavourable lipid profiles (50), whereas others report no 
change in lipid profile on either cessation or continuation 
of rhGH therapy during transition (16, 20, 40). A 
study of KIMS database (Pfizer International Metabolic 
Database) reported that those who were older at first 
starting childhood rhGH (short duration of childhood 
rhGH replacement) and had a longer time off rhGH 
during transition were more likely to have higher total 
cholesterol and triglyceride levels during transition (51).
Cardiac structure and performance: At final height, 
cross-sectional echocardiographic studies indicate that all 
cardiac dimensions of adolescents with GHD who were 
treated with rhGH during childhood were significantly 
smaller than their age- and sex-matched healthy controls 
after withdrawal of rhGH (5.7 ± 4.5 years), whereas 
reinstituting rhGH results in a significant increase in LV 
mass and LV mass index after 16–24 months (52) with 
improvement in endothelial function within the first 
6 months of restarting rhGH (53).
There is also conflicting data on alterations in carotid 
artery intima-media thickness (IMT), a surrogate marker 
of early atherosclerosis with increasing in IMT thickness, 
in subjects with CO-GHD. Murata and coworkers showed 
a significantly higher IMT in adults with CO-GHD 
compared with both adults with AO-GHD and healthy 
controls (54). However, this alteration in IMT was not 
evident in adolescents with CO-GHD during and after 
discontinuation of rhGH (48, 55). A study involving 23 
subjects with CO-GHD (14-IGHD) (aged 15–20 years) 
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showed that 6 months off rhGH in adolescents with 
confirmed GHD did not result in a significant alteration of 
the common carotid arteries, whereas in adolescents who 
were not confirmed to have GHD, IMT increased during 
rhGH treatment and reversed to normal 12 months after 
rhGH withdrawal (48).
In summary, the current evidence suggests that dis-
continuation of rhGH during transition is associated with 
a pro-atherogenic lipid profile; however, the effects of 
recommencement of rhGH treatment and a prolonged 
period off treatment are less clear. There is no evidence 
demonstrating that discontinuation of rhGH therapy 
during transition has any detrimental consequences on 
the cardiovascular system in the short or long term.
Glucose metabolism: Few studies have investigated 
CO-GHD and its replacement on insulin and glucose 
metabolism during transition in relation to concomitant 
changes in body composition and metabolism. After 
cessation of rhGH at final height, some studies reported 
an increase in insulin sensitivity as estimated by either 
means of a hyperinsulinemic euglycaemic clamp (56) 
or homeostasis model assessment (HOMA) (40) and 
an increase in fasting glucose (39) in those who had 
persistent GHD, with similar changes reported elsewhere 
in those who were not confirmed to be GH deficient at 
final height (57). Inversely, significantly impaired insulin 
resistance as measured by HOMA was recorded within 
6 months off rhGH, but returned to baseline levels after 
6 months after restarting rhGH replacement (48). At 
2 years of resuming rhGH therapy during transition, there 
was an insignificant or limited effect on insulin residence, 
insulin sensitivity and glycosylated haemoglobin (HbA1c) 
(16, 20, 56). In addition to the variation in techniques used 
to assess glucose homeostasis in these studies, other factors, 
particularly body compositions and short-term duration, 
results in limited evidence with regards to impairment of 
glucose homeostasis in GHD and rhGH replacement during 
transition. Long-term studies are necessary to identify the 
influence of different aspects of GHD and replacement on 
glucose homeostasis during transition.
Generally, there is weak evidence that GHD or rhGH 
replacement induces an increase in the risk of type 2 
diabetes (T2DM) in subjects with GHD. With regard to 
GHD, the KIMS database has demonstrated that the 
prevalence of T2DM in untreated adults with AO-GHD and 
hypopituitarism was higher than expected with an overall 
standardised prevalence proportion ratio (1.13 (95% CI: 
1.04–1.23%)), which was largely to be explained by high 
BMI and the adverse body composition (58). In terms 
of rhGH replacement, there is an uncertain relationship 
between rhGH treatment and the risk of T2DM, in 
particular in those with GHD, and whether rhGH therapy 
leads to increased risk of diabetes has not been established 
yet. Paediatric studies demonstrated modest increases in 
the incidence of T2DM in rhGH-treated children with 
predisposed risks relative to the general population, but 
not in those with GHD individually (59, 60).
In conclusion, in GHD, there is insufficient evidence 
available to conclude whether or not rhGH therapy in child-
hood or transition alters insulin sensitivity and increases 
the risk of T2DM in adulthood. More research is needed to 
clarify the elements of the dual effects of GH during transi-
tion in adolescents with CO-GHD with regards to both the 
impact on body composition/BMI and insulin resistance.
Quality of life
The health-related quality of life (QoL) issue has emerged 
as an important aspect in consideration of rhGH therapy 
in adulthood, but not during childhood or transition (8). 
In relation to QoL in individuals with CO-GHD, some 
studies reported that children and adolescents with GHD 
have some difficulties with psychosocial functioning, 
mood, behaviour and cognitive ability (61) despite the 
achievement of acceptable final height (62). A retrospective 
study suggested that adolescents with CO-GHD who were 
not treated with rhGH after attaining final height have 
some psychological difficulties with self-confidence and 
social contact, and this was worse in those who were 
either rhGH-treated after the age of 12 years or those who 
were shorter at the start of treatment (61). A report from 
the KIMS database showed a positive relationship between 
height gain during childhood treatment and improvement 
in QoL at transition and an inverse relationship between 
QoL and duration off rhGH therapy with a longer period 
off rhGH associated with a poorer QoL (51). Re-instituting 
rhGH treatment has a significant positive change in health-
related QoL aspects (51, 63). However, longitudinal studies 
evaluated the effects of discontinuation and resumption 
of rhGH treatment on QoL in young adults with CO-GHD 
and showed that discontinuation of rhGH treatment for 
1 year leads to a decrease in QoL within 6 months, which 
is counteracted in 3–6 months after re-initiating rhGH 
therapy (6, 64). This was disputed in follow-up and RCT 
studies showing that QoL is less effected in adolescents 
with GHD measured after discontinuation rhGH at 
final height (63) with no difference in being off rhGH 
therapy and after re-commencing rhGH (16, 20, 65). 
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However, using different questionnaire tools (generic and 
disease-specific questionnaires) which assess different 
dimensions of health-related quality of life in adolescents 
with CO-GHD makes comparisons of the outcomes of 
these studies difficult.
In summary, there is variability in the assessment of QoL 
by different studies in terms of the instruments used and the 
effects measured which may reflect the different outcome 
results in QoL. In addition, QoL is multifactorial and 
factors such as short stature combined with other pituitary 
hormones deficiency may influence QoL in this particular 
group of patients. To date, there is no clear consensus on 
the appropriate QoL measurement tools in children and 
adolescents with GHD. Therefore, there is currently no 
evidence of reduced QoL that rhGH may have beneficial 
effects on QoL in subject with CO-GHD during transition.
Conclusions
GHD is an important condition that has detrimental 
effects on both physical and psychological health 
throughout life, whereas rhGH therapy shows benefits in 
both children and young adults with GHD throughout 
each stage of their life. It seems from the current data that 
rhGH has less direct impact on bone density, with a greater 
impact on body composition and cardiovascular risk 
factors, including improvement in serum lipid profiles, 
and to a lesser extent on insulin sensitivity and QoL. 
Even with scarce evidence, substantial short-term studies 
during transition revealed that untreated GHD has a risk 
of alteration in somatic and metabolic consequences, 
although it is difficult to establish whether these mild 
alterations represent the early long-term consequences 
and whether subsequent rhGH treatment improves 
long-term health. Larger studies of longer duration of 
rhGH therapy will be required to determine whether the 
metabolic alterations in adolescent GH-deficient patients 
persist in later adulthood and if recommencement of 
rhGH therapy has a positive impact on these aspects.
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